Pharmcodynamics (PD) and Pharmacokinetics (PK) of E7389 (Eribulin, Halichondrin B Analog) During a Phase I Trial in Patients with Advanced Solid Tumors: A California Cancer Consortium Trial

BACKGROUND: The California Cancer Consortium completed a Phase I trial of E7389 (eribulin mesylate), an analog of the marine natural product halichondrin B. This trial was to determine the pharmacodynamics, pharmacokinetics, and MTD of E7389 administered by bolus injection weekly for three weeks out...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Chemother Pharmacol
Prif Awduron: Morgan, Robert J., Synold, Timothy W., Longmate, Jeffrey A., Quinn, David I, Gandara, David, Lenz, Heinz-Josef, Ruel, Christopher, Xi, Bixin, Lewis, Michael D., Colevas, A. Dimitrios, Doroshow, James, Newman, Edward M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694049/
https://ncbi.nlm.nih.gov/pubmed/26362045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2868-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg